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For the first time, a series of 25 pseudo-octahedral pyridylphosphinate metal complexes (Ru, Os, Rh, Ir) has been 
synthesised and assessed in biological systems. Each metal complex incorporates a pyridylphosphinate ligand, a 
monodentate halide and a capping η6-bound aromatic ligand. Solid- and solution-state analyses of two complexes reveal a 
structural preference for one of a possible two diastereomers. The metal chlorides hydrolyse rapidly in D2O to form a 1:1 
equilibrium ratio between the aqua and chloride adducts. The pKa of the aqua adduct depends upon the pyridyl 
substituent and the metal but has little dependence upon the phosphinate R’ group. Toxicity was measured in vitro against 
non-small cell lung carcinoma H460 cells, with the most potent complexes reporting IC50 values around 50 μM. Binding 
studies with selected amino acids and nucleobases provide a rationale for the variation in toxicity observed within the 
series. Finally, an investigation into the ability of the chelating amino acid L-His to displace the phosphinate O‒metal bond 
shows the potential for phosphinate complexes to act as prodrugs that can be activated in the intracellular environment.
Introduction 
In the field of bioinorganic chemistry, platinum group metal 
complexes have found application in cellular imaging,
1
 in enzyme 
inhibition
2
 and as molecular probes of biological activity.
3
 The 
therapeutic anticancer activity these complexes is also often probed 
both in vitro and in vivo.
4
 In the context of therapeutics, the 
advantages that metal complexes offer over purely organic species 
include: a variety of metal geometries and coordination numbers, 
allowing access to intricate 3-dimensional structures; numerous 
metal oxidation states, allowing redox-activated drugs; tuneable 
ligands to vary sterics and electronics about the metal centre; 
exchangeable ligands, for in situ activation and binding to 
biomolecules; simple and modular syntheses, allowing rapid 
determination of structure to activity relationships. Despite the 
wide-spread clinical use of the platinum-based drugs, cisplatin, 
oxaliplatin and carboplatin,
5
 there remains issues associated with 
side-effects, including dose-limiting systemic toxicities
6
 and 
acquisition of drug resistance, which reduce the efficacy and clinical 
utility of these drugs.
7
  
 One class of metal complexes that has shown great promise as 
alternatives to Pt drugs are the pseudo-octahedral piano stool 
complexes,
8
 in which a low-spin d
6
 metal ion is capped by an η
6
-
phenyl or η
5
-cyclopentadienyl ligand, with the remaining 3 
coordination sites occupied by tri- bi- or mono-dentate ligands. 
Over the past decades, many examples of piano stool metal 
complexes have been reported that show excellent in vitro
9
 and in 
vivo
10
 activity against cancers (Figure 1). Variation of each 
component of the piano stool arrangement alters the activity of the 
complex. For example, in the series [(η
6
-arene)Ru(en)Cl]PF6 a 3-fold 
increase in activity against human ovarian cancer cell line A2780 is 
observed when the arene is varied from benzene to biphenyl.
11
 
Similarly, modulation of the mono-dentate halide in the series 
[(η
6
-p-cym)Ru(p-Azpy-NMe2)X]PF6 from chloride to iodide results in 
a decrease in IC50, the concentration of complex required to inhibit 
cell proliferation by 50%, from 13 μM to 0.69 μM in the A2780 cell 
line.
12
 Finally, complexes with the same ligand can vary in activity, 
depending upon the central metal. In the 
[(η
6
-p-cym)M(picolinate)Cl] series, IC50  values (A2780 cell line) of 45 
μM
13
 and 4.5 μM
14
 were reported for the Ru and Os complexes, 
respectively. Beyond Ru(II) and Os(II), there are also a host of Ir(III) 
and Rh(III) piano-stool complexes, whose activity often surpasses 
that of related Ru(II) complexes.
15
 Although often not well 
understood, the mechanism of action of these complexes may 
involve DNA binding,
16
 interactions with histone proteins,
17
 redox 
modulation
18
 or enzyme inhibition.
19
   
 
 
Fig. 1 Examples of metal complexes assessed for their anticancer activity. 
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Scheme 1 General synthetic pathway and list of new complexes 
 
 The vast majority of reported piano stool complexes in the 
bioinorganic chemistry field incorporate polypyridyl, carboxylate or 
halide ligands. Only rarely are ligands explored that include 
elements other than C, N and O. However, there are a host of 
alternatives that may offer significant advantages over the more 
traditional ligand systems. In this study we present a novel ligand 
for platinum group metal complexes: the pyridylphosphinates. We 
report the synthesis, structural characterisation, aqueous 
properties and biological activities, including in vitro cytotoxicities, 
of a series of piano stool metal complexes incorporating the 
pyridylphosphinate ligand (Figure 1). Lanthanide complexes 
incorporating this ligand have found application in cellular 
imaging.
20
 However, the piano stool pyridylphosphinate complexes 
have never been studied. Advantages of the pyridylphosphinate 
ligand include: biocompatibility; the presence of a 
31
P-NMR 
spectroscopic handle; control over lipophilicity at phosphorus; 
modular synthesis allowing rapid structure-activity relationship 
profile and, finally, the presence a stereogenic phosphorus, which 
presents an opportunity to develop enantiomerically pure metal-
based complexes.
21  
Despite the host of piano stool complexes that have been 
reported, there is often a lack of information on biological 
behaviour, such as interactions between biologically relevant 
molecules (amino acids, proteins and nucleobases) and the metal 
complexes. This information is needed as the changes in structure 
of the complexes that take place in the cellular environment will 
have a profound effect upon the biological activity. Herein, we 
interrogate the behaviour of the novel pyridylphosphinate 
complexes in biological systems, by monitoring metal-halide 
hydrolysis, measuring pKa values of the resultant aqua complexes 
and carrying out detailed binding studies with selected 
biomolecules.  
Synthesis and Structural Characterisation 
 A series of complexes were synthesised in order to assess the 
factors that determine aqueous biological behaviour. Systematic 
variation in the metal‒arene combination, the metal-bound halide, 
the phosphorus R’ group and the pyridyl R group led to a library of 
25 new compounds (Scheme 1). Synthesis involves Pd-catalysed 
coupling of the phosphinate (HPO(OEt)R’) and bromo-pyridyl 
precursors.
22
 Quantitative hydrolysis of the phosphinate ester was 
followed by neutralisation with NaOMe and complexation with the 
appropriate metal dimer [(arene)MX2]2. Purification by 
recrystallisation from CHCl3/Et2O gave the final complexes with 30-
50% yields.
†  
The synthesis of complexes 7 and 8 (Scheme 2) proceeds via the 
4-fluoropyridylphosphinate intermediate L1, which undergoes 
nucleophilic aromatic substitution to form the electron-rich 4-OCD3- 
or electron-poor 4-Cl-pyridylphosphinate ligand, depending upon 
hydrolysis conditions.  
Single crystals suitable for X-ray diffraction studies were grown 
of complexes 3 and 20 (Figures 2A and 3). Complex 3 crystallises in 
the monoclinic crystal system and the P21/c space group and 
displays the expected pseudo-tetrahedral geometry, with the η
6
-p-
cymene occupying one vertex. Ru‒Cl (2.4155(6) Å), Ru‒O 
(2.0809(14) Å) and Ru‒N (2.1109(17) Å) bond lengths are almost 
identical to those reported for the analogous picolinate complex 
[(η
6
-p-cym)Ru(picolinate)Cl],
13
 however, the N‒Ru‒O bite angle is 
slightly larger in complex 3, at 80.50(6)° (bite angle in picolinate 
complex is 77.95(7)°), reflecting the larger size of the phosphinate 
group. Intriguingly, of the four possible stereoisomers (R or S at Ru 
and P, denoted RuR/S and PR/S, respectively), only one enantiomeric 
pair is observed in the solid state structure – RuSPR and RuRPS. 
1
H-
NMR indicates that a single diastereomer is also present in solution, 
evidenced by one set of diastereotopic p-cymene protons in the 
region 5 – 6 ppm (Figure 2B). The origin of this stereoselectivity, 
which has also been observed in lanthanide pyridylphosphinate 
complexes,
23
 can be rationalised in terms of the steric interactions 
between the p‒cymene ligand and the P-phenyl group, which are 
 
 
Scheme 2 
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Fig 2 (A) X-ray crystal structure of complex 3 and (B) 1H-NMR spectrum (CD3OD, 298 K, 400 MHz,), with expansions of the single set of diastereotopic p-
cymene protons and of the two methyl groups. 
 
minimised in the observed diastereomer. Weak intramolecular 
hydrogen bonds between the P=O and p-cymene methyl-H (2.587 
Å) and the P-phenyl and pyridyl methyl-H (3.065 Å) may also 
influence the observed stereochemistry. In solution, slight 
broadening of the pyridyl Me peak reflects its proximity to the P-
phenyl aromatic system, but the presence of a sharp singlet peak 
for the p-cymene Me group suggests free rotation of the p-cymene 
ligand, as is expected for η
6
-arene‒metal bonds.
24 
The solid state structure of the Cp*-Ir complex 20 (Figure 3) 
shows several differences from complex 3, including a Cc space 
group, longer bond lengths between the central metal and 
coordinated ligands and a wider N‒metal‒O bite angle of 
82.00(11)°. Despite the presence of the less sterically challenging P-
methyl phosphinate ligand, once again only a single 
diastereoisomer is observed – IrSPR and IrRPS. No intramolecular H-
bond interactions can be observed in the crystal structure, which 
presents further questions over the origin of this stereoselectivity. It 
may be that stereoselectivity originates from the initial attack of the 
phosphinate ligand on the metal dimer, during the formation of the 
complex.
 
Aqueous Behaviour of the Complexes 
To gain an understanding of the intracellular behaviour of metal 
complexes with biological application, it is essential to have an 
appreciation of the aqueous behaviour of new compounds. Upon 
dissolving complex 1 in a D2O : CD3OD (9 : 1) mix, equilibrium is 
established between the chloride (complex 1) and aqua (complex  
 
 
Fig 3. X-ray crystal structures of Ir complex 20. 
1a) species (Figure 4). 
1
H-NMR of the p-cymene protons indicates 
that an approximate 1 : 1 (chloride : aqua) equilibrium is reached 
within 5 min and does not shift over the course of 24 h (Figure 4A). 
To confirm that the observed species are the chloride and aqua 
adducts, the complex was dissolved in 100 mM NaCl (Figure 4B) and 
in aqueous AgNO3, followed by filtration of AgCl (Figure 4C), leading 
to the selective formation of the chloride and aqua adducts, 
respectively, each showing a characteristic set of diastereotopic 
protons. The analogous Ru-iodide complex also undergoes rapid 
hydrolysis with around 60% of the complex remaining as the intact 
iodide species. 
At the extracellular chloride concentration (approx. 100 mM), 
the pyridylphosphinate complexes remains intact as the chloride 
adduct, but at lower intracellular chloride concentration (approx. 20 
mM in cytoplasm)
25
 significant amounts of the aqua adduct are 
present. With this in mind, we sought to measure the pKa of the 
bound water molecule and to establish how the pKa varies with the 
 
 
Fig 4 1H-NMR spectra (D2O : CD3OD 9:1, 298 K, 400 MHz) of (A) complex 1 
and 1a at approximately 1:1 equilibrium ratio, (B) chloride complex 1, 
following addition of 100 mM NaCl and (C) aqua complex 1a, following 
addition of AgNO3 and filtration of AgCl. 
δ / ppm
a
a
b
b
(A)
(B)
20
(A)
(B)
(C)
δ / ppm
1 1a
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Fig 5 Measurement of the pKa* of aqua complex 5a by monitoring the 
31P-
NMR spectrum (D2O : CD3OD 9:1, 298 K,  162 MHz) as a function of pH*. For 
Ru complexes, at approx. pH* > 11 formation of the hydroxy-bridged dimer 
D1 is observed. 
 
choice of central metal and coordinated ligands. pKa* (pKa 
measured in D2O) values were measured by monitoring the 
31
P- and 
1
H-NMR spectra of selected aqua complexes in D2O : CD3OD (9 : 1) 
as a function of pH* (pH values in D2O solution, Figure 5), according 
to established procedures
25
 (see ESI
†
 for full details). pKa* values 
were converted to pKa values using the equation  
pKa = 0.929pKa* + 0.42.
26
 By comparing pKa values of selected aqua 
complexes (Table 1), it is apparent that a more electron donating 
pyridyl ligand leads to a higher pKa. This is shown by the increase in 
values in the order 5a < 3a < 7a for complexes with 4-Me, 3-Me and 
OCD3 pyridyl substituents, respectively. This order reflects the 
higher pH required to deprotonate H2O bound to a more electron-
rich metal centre. The phosphorus-bound R’ group has little effect 
on pKa, as can be seen by comparing values for 3a and 4a. Finally, as 
expected, the pKa value for the Ir complex 20a is lower than that of 
the equivalent Rh complex 25a, reflecting the increased metal‒
oxygen bond strength of the heavier congener.
27
 For each of the 
studied Ru complexes, the hydroxyl-bridged dimer D1 (Figure 5) 
forms at strongly basic pH (typically >pH 11), with concomitant loss 
of the pyridylphosphinate ligand.
†
 The formation of this dimeric 
species from Ru piano stool complexes at elevated pH has been 
observed previously and the dimer is known to be non-cytotoxic.
28
 
NMR experiments indicate that dimer formation is partially 
reversible upon lowering the pH, but that complete regeneration of 
the starting complex does not take place. 
 
Table 1 pKa values for selected aqua complexes (D2O : CD3OD 9:1, 298 K). 
pKa* values were measured by monitoring changes in 
31P-NMR and 1H-NMR 
spectra and converted to pKa using the equation pKa = 0.929pKa* + 0.42.
26 
Complex R R’ {M(arene)} pKa 
3a 
4a 
5a 
7a 
20a 
25a 
3-Me 
3-Me 
4-Me 
4-OCD3 
4-Me 
4-Me 
Ph 
Me 
Ph 
Ph 
Me 
Me 
{Ru(p-cymene)} 
{Ru(p-cymene)} 
{Ru(p-cymene)} 
{Ru(p-cymene)} 
{Ir(Cp*)} 
{Rh(Cp*)} 
9.34 ± 0.04 
9.18 ± 0.19 
7.76 ± 0.13 
10.08 ± 0.05 
9.31 ± 0.07 
10.95 ± 0.04 
 
 
Table 2 IC50 values for selected complexes measured using the MTT assay 
(72 h) against the non-small cell lung carcinoma H460 cell line. Entries are 
the mean value for data from at least three experiments. Complexes not 
included were found to have IC50 > 200 μM 
Complex R R' M arene X IC50 / μM 
1 H Ph Ru cym Cl >200 
10 H Ph Ru cym I 65 ± 12 
11 H Me Ru cym I >200 
18 H Ph Ir Cp* Cl >200 
19 H Me Ir Cp* Cl >200 
20 4-Me Me Ir Cp* Cl 140 ± 40 
21 H Ph Ir Cp* I 52 ± 2 
22 H Me Ir Cp* I 53 ± 4 
25 4-Me Me Rh Cp* Cl 135 ± 17 
Cisplatin - - - - - 0.80 ± 0.01 
Cytotoxicity Studies 
The toxicity of each complex was assessed against non-small cell 
lung carcinoma H460 cells. Each complex was incubated with H460 
cells for 96 h at concentrations ranging from 0.1 to 200 μM 
(aqueous media containing 0.1% DMSO) and IC50 values were 
measured using the MTT assay (see ESI
†
 for details). The solubility 
of complexes at these concentrations was assessed to ensure the 
compounds are fully dissolved (see ESI
†
 for details). Selected results 
are shown in Table 2 and represent the mean value for data from at 
least three experiments. All Ru complexes incorporating chloride 
ligands are non-toxic up to 200 μM. The most cytotoxic species are 
the iridium-Cp* complexes 21 and 22, each with IC50 values of 50 ± 
5 μM, respectively. The presence of the iodide ligand appears to 
play an important role in the observed toxicity, as the analogous 
chloride complexes, 18 and 19, gave IC50 values >200 μM. 
Comparing complexes 21 (P-phenyl) and 22 (P-methyl), it would 
appear that the phosphorus-R group has little influence upon the 
toxicity. However, this is not the case when comparing the Ru-p-
cymene complexes 10 and 11, for which the P-phenyl analogue has 
significantly greater cytotoxicity than the P-methyl complex. A 
comparison with cisplatin (IC50 = 0.80 ± 0.01 under the experimental 
conditions), shows that in general this class of complexes have low 
cytotoxicity. While ineffective as cytotoxic agents, this feature may 
bode well for uses in applications such as enzyme inhibitors. 
A general feature within this series is that the complexes 
incorporating monodentate iodide ligands have higher toxicities 
than the corresponding chloride complexes. The extent of 
hydrolysis of the iodide complexes is less than that of the chloride 
complexes, leading to the conclusion that a mechanism of action 
involving hydrolysis and DNA binding, as is often proposed for piano 
stool metal complexes, may not be the main mechanism of action 
operating for this series of complexes. Whatever the mechanism, 
the observation of higher toxicity for iodide complexes is consistent 
with previously published reports
12,30
 for both Ru- and Os-based 
anticancer complexes. Studies are ongoing to elucidate a potential 
mechanism of action for these species.  
Binding Studies 
In general, the Ru complexes herein have IC50 values greater than 
200 μM. In an attempt to understand this low cytotoxicity, binding 
studies were carried out with several biomolecules. Addition of  
37
38
39
40
41
42
2.0 4.0 6.0 8.0 10.0
δ
(3
1
P
) 
/ 
p
p
m
pH*
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Fig 6 Mass Spectra for complex 1a in the presence of (A) L-alanine, (B) 9-
ethylguanine, (C) L-histidine and (D) imidazole. Peaks labelled a – f correlate 
to peaks in Table 3. 
 
AgNO3 to complex 1 dissolved in D2O, followed by filtration of the 
resulting AgCl precipitate, gave the aqua adduct, 1a. Mass 
spectrometry and NMR spectroscopy (
1
H and 
31
P) were used to 
identify the presence and extent of biomolecule binding after 
addition of one and two equivalents of biomolecule to 1a, at 1 h 
and 16 h time-points (Figure 6 and Table 3). The biomolecules 
selected for investigation were L-alanine (L-Ala), L-threonine (L-Thr), 
L-histidine (L-His), imidazole and 9-ethylguanine (9-EtG). No 
evidence for binding between 1a and 1 equivalent of amino acids L-
Ala and L-Thr was observed after 1 h. In contrast, addition of 1 
equivalent of 9-EtG led to a peak in the mass spectrum 
corresponding to the 9-EtG adduct of 1a, following loss of H2O. 
1
H-
NMR analysis indicated the formation of a bond between Ru and N7 
on 9-EtG, with around 50% bound complex in solution. This mode of 
binding is consistent with previous reports that have proposed a 
mechanism of action for the anticancer behaviour of Ru complexes 
to involve DNA binding, leading to apoptosis.
16
 
Upon addition of 1 equivalent of L-His, an adduct was observed, 
consistent with replacement of H2O for L-His, binding though an 
imidazole N. When the sample was subjected to a second 
equivalent of L-His and left to equilibrate over 16 h, a species 
formed in which the pyridylphosphinate ligand is displaced and the 
L-His binds κ
3
 (Figure 7). The observed Ru‒(L-His) complex, 1c, is 
known to be non-cytotoxic
31
 and its formation presents a potential 
explanation of the low cytotoxicity of Ru chloride complexes 
described in this report. It follows that the higher cytotoxicity of the 
iodide-complexes, 10, 21 and 22, is due to the metal‒iodide bond 
being less labile towards aquation and therefore less likely to 
undergo decomplexation by chelating biomolecules. It should be 
noted that the only tested biomolecule able to displace the 
pyridylphosphinate ligand was L-His. Addition of 2 equivalents of 
imidazole (16 h) leads to 1 : 1 adduct formation, with loss of H2O, 
but no ligand displacement. The cytotoxicity of the displaced ligand 
of complex 1 (shown in Fig 7A) was assessed using the MTT assay 
and found to by non-cytotoxic up to 200 μM. In future studies it 
may be possible to tune the lability of pyridylphosphinate ligands,  
Table 3 Proposed species that give rise to mass peaks in Figure 6, upon 
addition of selected biomolecules. Tabulated m/z values a – f correspond to 
mass peaks in Figure 6. 
 
 
so that the complexes remain intact in the high chloride 
concentration of the extracellular medium but are able to release 
some useful payload within the cell where the chloride 
concentration is lower. 
Conclusions 
A series of 25 new piano-stool pyridylphosphinate complexes has 
been synthesised, characterised and assessed in biologically-
relevant systems. The properties of the complexes depend upon 
their various components – metal ion, arene, pyridyl substituent 
and P‒alkyl group – which can be varied with relative ease. 
Aqueous solubility and stability is good. Ru‒Cl complexes are non-
toxic up to 200 μM, which bodes well for their use as a scaffold for 
metal-based enzyme inhibitors. Ir‒I complexes are more toxic to 
cells, so may have the potential to act as anticancer agents,  
 
 
Fig 7 1H-NMR spectra (D2O : CD3OD 9:1, 298 K, 400 MHz) of (A) uncomplexed 
pyridylphosphinate ligand and (B) products of addition of 2 equivalents of L-
His to complex 1a, showing the decomplexation of the pyridylphosphinate 
ligand and the formation of L-His complex, 1c 
(A)
(B)
(C)
(D)
a
b
c
d
e f
Biomolecule m/z Species
L-Ala a: 454.3 [1a – H2O]
+
L-Thr 454.6 [1a – H2O]
+
9-EtG
b: 453.8 [1a – H2O]
+
c: 632.9
L-His d: 390.6
Imidazole
e: 454.0 [1a – H2O]
+
f: 522.4
1b
1c
1d
(A)
(B) +
δ / ppm
1c
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although toxicity remains low compared to cisplatin. It was 
discovered that decomplexation of the ligand from complex 1 
occurs in the presence of excess L-His, following hydrolysis of the 
Ru‒Cl bond. This has the potential to be exploited in the form of 
complexes that deliver and release useful payloads to the cell. The 
rate of aquation and the pKa of the resulting aqua species can be 
tuned by varying the pyridyl substiuent and the judicious choice of 
metal‒halide combination. Studies are ongoing to investigate the 
cell uptake, localisation and any potential antimetastatic behaviour 
of these exciting new complexes and to exploit the lability of the 
phenylphosphinate Ru bond to design responsive biologically active 
complexes. 
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